Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price reached a new 52-week high during trading on Wednesday after HC Wainwright raised their price target on the stock from $52.00 to $60.00. HC Wainwright currently has a buy rating on the stock. Hemab Therapeutics traded as high as $54.19 and last traded at $53.31, with a volume of 101491 shares traded. The stock had previously closed at $51.74.

COAG has been the topic of a number of other research reports. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective on the stock. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush reissued an “outperform” rating and issued a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Evercore assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Jefferies Financial Group raised their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Insider Transactions at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the acquisition, the insider directly owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders bought 72,467 shares of company stock worth $1,809,595.

Hemab Therapeutics Stock Up 3.6%

The company has a market cap of $2.50 billion and a price-to-earnings ratio of -2.24. The firm’s fifty day simple moving average is $37.46.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). On average, sell-side analysts predict that Hemab Therapeutics Holdings, Inc. will post -2.89 earnings per share for the current fiscal year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.